US2013303744A1PendingUtilityA1

Usp2a peptides and antibodies

60
Assignee: NUCLEA BIOTECHNOLOGIES INCPriority: Oct 26, 2011Filed: May 16, 2013Published: Nov 14, 2013
Est. expiryOct 26, 2031(~5.2 yrs left)· nominal 20-yr term from priority
Inventors:Patrick J. Muraca
G01N 33/57555G01N 33/575C07K 2317/76C07K 2317/75C07K 2317/24C07K 14/47C07K 7/08G01N 33/6854C12Q 1/6886G01N 33/573C12N 9/6421G01N 2800/56G01N 2800/52C12Q 1/37C07K 2317/34C12Q 2600/158C12N 9/6472C07K 16/40
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to novel USP2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A nucleic acid molecule encoding a protein or peptide molecule selected from the group consisting of SEQ ID NO, 1, SEQ ID NO. 2, and variants thereof. 
     
     
         2 . The nucleic acid molecule of  claim 1 , comprising at least about 5 nucleic acid bases to about 80 nucleic acid bases. 
     
     
         3 . The nucleic acid molecule of  claim 2 , further comprising at least about 10 nucleic acid bases to about 30 nucleic acid bases. 
     
     
         4 . The nucleic acid molecule of  claim 1 , wherein the nucleic acid molecule is a deoxyribonucleic acid (DNA) molecule. 
     
     
         5 . The nucleic acid molecule of  claim 1 , wherein the nucleic acid molecule is a ribonucleic acid (RNA) molecule. 
     
     
         6 . The nucleic acid molecule of  claims 1 , wherein the nucleic acid molecule further comprises a detectable label.

Join the waitlist — get patent alerts

Track US2013303744A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.